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Combining ECG Criteria for Left Ventricular Hypertrophy Improves
Risk Prediction in Patients With Hypertension
Peter M. Okin, MD; Darcy A. Hille, MSEMBA; Sverre E. Kjeldsen, MD, PhD; Richard B. Devereux, MD
Background-—Patients with hypertension with ECG left ventricular hypertrophy (LVH) have higher cardiovascular morbidity and
mortality, but single ECG criteria may underestimate risk. Whether continued presence or new development of ECG LVH by 2
criteria can further concentrate risk during blood pressure lowering is unclear.
Methods and Results-—Incident stroke, myocardial infarction, cardiovascular death, the composite of these outcomes, and all-
cause mortality were examined in relation to the presence of on-treatment ECG LVH by Cornell product and/or Sokolow-Lyon
voltage during a mean of 4.80.9 years follow-up in 9193 patients with hypertension randomized to losartan- or atenolol-based
regimens. Patients were categorized into 4 groups according to the presence or absence of ECG LVH by each criterion at baseline
and yearly during the study. At baseline, LVH by both criteria was present in 960 patients (10.4%). Compared with the absence of
ECG LVH by both criteria, persistence or development of ECG LVH by both criteria entered as a time-varying covariate was
associated with >3-fold increased risks of events in multivariable Cox analyses adjusting for randomized treatment, baseline risk
factors, and on-treatment heart rate and systolic and diastolic blood pressures. Patients with ECG LVH by either Cornell product or
Sokolow-Lyon voltage had 45% to 140% higher risks of all end points.
Conclusions-—Persistence or development of ECG LVH by both Cornell product and Sokolow-Lyon voltage criteria during
antihypertensive therapy is associated with markedly increased risks of cardiovascular end points and all-cause mortality. Further
study is indicated to determine whether additional therapy in these patients can reduce their risk.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00338260. ( J Am Heart Assoc. 2017;6:
e007564. DOI: 10.1161/JAHA.117.007564.)
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L eft ventricular hypertrophy (LVH) detected by 12-leadECG1–3 and by echocardiography4–8 are common man-
ifestations of preclinical cardiovascular disease that strongly
predict cardiovascular morbidity and mortality. Antihyperten-
sive therapy aimed at reducing blood pressure (BP) can
produce regression of LVH,3,4,9–15 and regression of ECG LVH
and prevention of progression to LVH have been associated
with a reduced risk of cardiovascular morbidity and mortal-
ity.2,3,12,13,16–20 Importantly, the improved prognosis with
regression of ECG LVH is independent of reductions in BP
during antihypertensive therapy.16–20 This increased risk
associated with failure to regress LVH highlights the impor-
tance of better identifying patients who remain at residual risk
despite aggressive BP lowering.16–20
The well-recognized limited sensitivity of any one ECG LVH
criterion as compared with imaging modalities has been put
forward as a limitation of ECG-dependent approaches to LVH
diagnosis,21 despite findings that imaging and ECG methods
appear to similarly track prognosis17,21,22 and may provide
complimentary information.21,23–28 Based on the limited sensi-
tivity of single ECG criteria, investigators have demonstrated
that using both Cornell product (CP) and Sokolow-Lyon voltage
(SL) duration criteria together can increase sensitivity and
population prevalence for detection of echocardiographic LVH,
albeit with some loss of specificity,29,30 and that the presence of
both of these criteria on ECG was associated with higher left
ventricular (LV) mass index and a greater prevalence of
echocardiographic LVH than either criterion alone or neither.31
The finding that different ECG LVH criteria identify different
populations of patients at potentially increased risk16,29–31 and
the additive value of ECG and imaging-based LVH for risk
stratification21,23–28 suggests an opportunity to better track risk
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by combining 2 ECG LVH criteria with complimentary prognostic
power. In this scenario, it might be predicted that the mutual
absence of LVH by both criteria would be associated with the
lowest risk, the presence of LVH by both criteria with the highest
risk, and the presence of LVH by one or the other with
intermediate risk. The LIFE (Losartan Intervention for Endpoint
Reduction) study17–20 recruited patients with ECG LVH by either
CP and/or SL before enrollment, tracked the magnitude of ECG
LVH by both criteria throughout follow-up, and demonstrated
that on-treatment CP and SL criteria separately predicted
cardiovascular risk but did not examinewhether combining the2
ECG LVH criteria could improve risk stratification. Therefore, the
present post hoc analysis of data from the LIFE study was
undertaken to examine whether the continued presence or new
development of ECG LVHby bothCP andSLwas associatedwith
increased risk of cardiovascular events and cardiovascular and
all-cause mortality compared with continued absence or
regression of ECG LVH by both of these criteria, and whether
the presence or development of LVH by either CP or SL is
associated with intermediate elevation of risk.
Methods
Patients
The LIFE study17–20,32 enrolled 9193 patients with hyperten-
sion who had ECG LVH by CP33 and/or SL criteria34 on a
screening ECG in a prospective, double-blind randomized
study that compared cardiovascular morbidity and mortality
with use of losartan- as opposed to atenolol-based treatment.
The study was approved by all ethics committees concerned.
As described in detail elsewhere,17–20,32 eligible patients for
LIFE were men and women aged 55 to 80 years with
previously untreated or treated essential hypertension with
mean seated BP in the range of 160 to 200/95 to
115 mm Hg after 1 and 2 weeks on placebo who had not
had a myocardial infarction (MI) or stroke within 6 months
and did not require treatment with a b-blocker, angiotensin-
converting enzyme inhibitor or angiotensin II type 1 receptor
antagonist. Institutional review board approval was obtained
and all participants gave informed written consent.
Treatment Regimens
Blinded treatment was begun with losartan 50 mg or atenolol
50 mg daily and matching placebo of the other agent, with a
target BP of ≤140/90 mm Hg. During clinic visits at frequent
intervals for the first 6 months and at 6-month intervals
thereafter, study therapy could be uptitrated by addition of
hydrochlorothiazide 12.5 mg, followed by an increase in
blinded losartan or atenolol to 100 mg daily. In patients whose
BP was still not controlled, additional open-label upward
titration of hydrochlorothiazide and, if necessary, institution
of therapy with a calcium channel blocker or additional other
medications (excluding angiotensin II type 1 receptors or b-
blockers or angiotensin-converting enzyme inhibitors) was
added to the double-blind treatment regimen.17–20,32
Electrocardiography
ECGs were obtained at study baseline, at 6 months, and at
yearly follow-up intervals until study termination or patient
death. ECGs were interpreted at the Core Laboratory at
Sahlgrenska University Hospital/€Ostra in G€oteborg, Sweden,
by experienced readers blinded to clinical information. QRS
duration was measured to the nearest 4 ms and the QRS
amplitudes to the nearest 0.5 mm (0.05 mV). The product of
QRS duration times the CP combination (RaVL+SV3, with 6 mm
added in women32,33) >2440 mmms or SL (SV1+RV5/6)
>38 mmwere used to identify LVH.17–20,32–34 A sex adjustment
of 6 mm, as opposed to the originally proposed 8 mm,17 was
employed based on studies published when the LIFE study was
getting started, suggesting that a higher threshold in women
was necessary to maintain specificity.35,36
End Point Determination
The LIFE study used a composite end point of cardiovascular
death, nonfatal MI, or nonfatal stroke, according to previously
defined criteria.32 These end points and the secondary end
Clinical Perspective
What Is New?
• The combination of 2 different ECG criteria for left
ventricular hypertrophy can improve risk stratification
compared with either criterion alone.
• The persistence or development of ECG left ventricular
hypertrophy by both Cornell product and Sokolow-Lyon
voltage was associated with >3-fold increased risks of
myocardial infarction, stroke, cardiovascular mortality, the
composite end point of these 3 prior outcomes, and all-
cause mortality after adjusting for other known or sus-
pected predictors of risk.
What Are the Clinical Implications?
• The use of both Cornell product and Sokolow-Lyon voltage
together can aid clinicians in risk stratification of patients
with hypertension.
• These findings further suggest that patients with persis-
tence or development of new left ventricular hypertrophy by
both criteria might benefit from additional therapy aimed at
regressing their left ventricular hypertrophy, but further
study of this issue is needed.
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point of all-cause mortality were ascertained and then verified
by an expert end point committee who were blinded to ECG
results when classifying possible morbid events.17–20,32
Statistical Analyses
Data management and analysis were performed with SPSS
version 22 software (IBM). Data are presented as meanSD
for continuous variables and proportions for categorical
variables. Patients were classified into 4 groups according
to the presence or absence of ECG LVH by both CP and SL.
Differences in prevalence between groups were compared
using chi-square analyses, and mean values of continuous
variables were compared using 1-way ANOVA.
Event rates in relation to the presence or absence of LVH
by CP and SL at baseline were calculated from Kaplan–Meier
survival estimates. The relation of the presence or absence of
LVH by CP and/or SL to the risk of events was assessed using
Cox proportional hazards models, with baseline and subse-
quent determinations of the presence or absence of LVH by
CP and SL entered as time-varying covariates.17–20 Initial
analyses were performed with CP and SL LVH as separate
variables in univariate and multivariate Cox models and then
with LVH classified by these variables into 4 groups, with the
group with no LVH by either criterion serving as the reference
group. Baseline risk factors and a treatment group indicator
were included as standard covariates, and baseline and
subsequent systolic and diastolic BPs and heart rate
measurements were entered as time-varying covariates. The
95% confidence interval (CI) of each hazard ratio (HR) was
calculated from the estimated coefficients and their standard
errors. The relationship of the combination of CP and SL LVH
to the composite end point was further examined in relevant
subgroups of the study population using the same multivari-
able Cox analysis as noted above and differences in the
predictive value between subgroups tested by examining the
interaction between the combined LVH variable and each
subgroup variable in the overall population. For all tests, a 2-
tailed P<0.05 was required for statistical significance.
Results
At baseline, LVH by both criteria was present in 960 patients
(10.4%). Baseline clinical and demographic characteristics of
patients in relationship to the presence or absence of ECG
LVH by CP and SL at study baseline are shown in Table 1.
Table 1. Study Baseline Demographic and Clinical Characteristics in Relation to the Presence or Absence of ECG LVH by Both CP
and SL at Baseline
Variables CP/SL (n=2023) CP+/SL (n=5220) CP/SL+ (n=990) CP+/SL+ (n=960) P Value
Age, y 66.17.1 67.27.0 66.57.0 67.76.8 <0.001
Female sex, % 56.7 58.4 32.5 46.0 <0.001
Black race, % 5.3 4.0 13.6 8.5 <0.001
Diabetes mellitus, % 11.6 14.5 10.1 10.4 <0.001
History of ischemic heart disease, % 13.0 16.4 18.0 17.9 <0.001
History of myocardial infarction, % 5.2 6.6 6.3 6.1 0.214
History of arrhythmia, % 5.2 7.0 8.0 9.8 <0.001
History of stroke, % 3.6 4.3 5.7 5.2 0.031
History of heart failure, % 0.8 2.1 1.1 3.1 <0.001
History of peripheral vascular disease, % 5.7 5.3 5.7 7.6 0.043
Current smoker, % 17.4 13.8 23.1 20.7 <0.001
Prior antihypertensive treatment, % 71.8 73.4 67.9 70.9 0.003
Randomized treatment (% losartan) 50.5 50.0 49.2 50.8 0.870
Body mass index, kg/m2 27.94.7 28.74.8 25.53.8 26.84.6 <0.001
Serum glucose, mmol/L 5.902.03 6.142.31 5.801.99 5.872.02 <0.001
Total cholesterol, mmol/L 6.031.12 6.081.13 5.851.08 6.051.15 <0.001
HDL cholesterol, mmol/L 1.500.43 1.480.43 1.540.45 1.510.44 <0.001
Creatinine, lg/mmol/L 85.419.7 85.819.4 92.323.0 90.721.0 <0.001
UACR, mg/mmol/L 4.716.1 8.038.8 9.738.7 9.228.6 <0.001
CP indicates Cornell product; HDL, high-density lipoprotein; LVH, left ventricular hypertrophy; SL, Sokolow-Lyon voltage; UACR, urine albumin/creatinine ratio.
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Patients across ECG LVH groups differed significantly with
respect to age, sex, race, prevalent diabetes mellitus, history
of ischemic heart disease, arrhythmia, stroke, peripheral
vascular disease, smoking, prior antihypertensive treatment,
body mass index, serum glucose, creatinine, total and high-
density lipoprotein cholesterol levels, and urine albumin/
creatinine ratio. Compared with patients without LVH by
either criterion, patients with ECG LVH by both criteria tended
to be older, were less likely to be women, have diabetes
mellitus, and received prior antihypertensive therapy. They
were more likely to be black and a current smoker; have a
history of ischemic heart disease, arrhythmia, stroke, and
peripheral vascular disease; and had lower body mass index
and serum glucose levels and higher serum creatinine and
urine albumin/creatinine ratios.
BP and ECG LVH measurements at baseline and changes in
these measurements between baseline and last in-study
determination in relation to the presence or absence of ECG
LVH by CP and SL at study baseline are shown in Table 2.
Patients across ECG LVH groups differed significantly with
respect to all baseline BP and ECG measurements and for all
changes in these measurements, with the exception of change
in heart rate. Baseline levels of QRS duration, CP, and SL
varied, as would be predicted by group definition. Changes in
systolic and diastolic BPs were greatest in patients with ECG
LVH by both criteria, while regression of ECG LVH during
treatment was higher in groups defined by the presence of
LVH by that criterion at baseline, and greatest among patients
with ECG LVH by both criteria at study baseline.
During mean follow-up of 4.80.9 years, MI occurred in
386 patients (4.2%); stroke in 541 patients (5.9%); cardiovas-
cular death in 438 patients (4.8%); the LIFE composite end
point of cardiovascular death, MI, or stroke in 1096 patients
(11.9%); and all-cause mortality in 814 patients (8.9%).
Univariate and multivariable Cox analyses for the prediction
of these end points by CP or SL LVH separately are shown in
Table 3. Compared with the absence of LVH by each criterion,
the presence of LVH by either SL or CP was associated with
39% to 128% increased unadjusted risks of these outcomes and
from 14% to 69% increased adjusted risk of all outcomes in
multivariable Cox models that adjusted for other risk factors.
Compared with each LVH criterion alone (Table 3), the
combination of CP and SL further concentrates the risk of all
end points (Figures 1 and 2). Rates of each outcome in
relation to the presence or absence of LVH by CP and SL at
study baseline are shown in Figure 1. For all outcomes, event
rates varied significantly across groups and were lowest in
patients who did not have LVH, intermediate in patients with
LVH by either CP or SL, and highest in patients with LVH by
both criteria, with 2.5- to 3.5-fold higher event rates among
patients with LVH by both criteria than in those without ECG
LVH by either.
The risk of cardiovascular morbidity and cardiovascular and
all-cause mortality in relation to the on-treatment presence or
absence of ECG LVH by both CP and SL treated as time-
varying covariates is shown in Figure 2. In univariate Cox
analyses, the persistence or development of new ECG LVH
was associated with significantly higher risks of all events:
Table 2. Study Baseline and Change From Study Baseline to Last In-Study Measurement of BP, ECG LVH, QRS Duration, and Heart
Rate in Relation to the Presence or Absence of ECG LVH by Both CP and SL at Baseline
Variables CP/SL (n=2023) CP+/SL (n=5220) CP/SL+ (n=990) CP+/SL+ (n=960) P Value
Baseline measurements
Systolic BP, mm Hg 17214 17414 17614 176143 <0.001
Diastolic BP, mm Hg 988 989 979 989 <0.001
CP, mmms 2065393 3212897 1715518 34541239 <0.001
SL, mm 26.47.3 25.76.8 44.95.9 45.36.4 <0.001
QRS duration, ms 92.811.5 105.719.5 96.69.4 103.818.5 <0.001
Heart rate, beats per min 74.111.2 74.211.1 72.210.7 73.011.3 <0.001
Change from baseline to last measurement
Systolic BP, mm Hg 27.718.6 29.419.4 30.820.2 31.321.4 <0.001
Diastolic BP, mm Hg 16.810.1 17.210.2 16.810.6 17.811.0 <0.001
CP, mmms 13659 270852 13790 4281140 <0.001
SL, mm 2.56.0 2.86.5 7.68.4 8.69.1 <0.001
QRS duration, ms 2.711.5 1.512.3 1.413.1 1.413.2 <0.001
Heart rate, beats per min 4.812.7 5.313.0 5.112.6 4.212.7 0.091
BP indicates blood pressure; CP, Cornell product; LVH, left ventricular hypertrophy; SL, Sokolow-Lyon voltage.
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Table 3. Univariate and Mulitvariable Cox Models for the Prediction of Outcomes According to On-Treatment LVH by Either CP or
SL Treated as Time-Dependent Covariates
Outcomes
CP LVH SL LVH
HR 95% CI P Value HR 95% CI P Value
Univariate
MI 1.53 1.25–1.88 <0.001 1.62 1.25–2.10 <0.001
Stroke 1.44 1.21–1.71 <0.001 2.28 1.87–2.10 <0.001
Cardiovascular death 1.80 1.48–2.19 <0.001 2.11 1.69–2.64 <0.001
Composite end point 1.52 1.34–1.71 <0.001 2.00 1.73–2.31 <0.001
All-cause mortality 1.39 1.21–1.60 <0.001 2.05 1.74–2.43 <0.001
Multivariable*
MI 1.28 1.05–1.49 0.014 1.33 1.14–1.55 0.009
Stroke 1.21 1.07–1.34 0.010 1.69 1.35–2.11 <0.001
Cardiovascular death 1.37 1.11–1.70 0.004 1.53 1.19–1.98 0.001
Composite end point 1.17 1.03–1.34 0.021 1.50 1.27–1.76 <0.001
All-cause mortality 1.14 1.04–1.33 0.017 1.57 1.30–1.89 <0.001
CI indicates confidence interval; CP, Cornell product; HR, hazard ratio; LVH, left ventricular hypertrophy; SL, Sokolow-Lyon voltage.
*Adjusted for randomized treatment, age, sex, prevalent diabetes mellitus, history of stroke, myocardial infarction (MI), ischemic heart disease, heart failure, peripheral vascular disease or
prior antihypertensive treatment, baseline serum cholesterol, high-density lipoprotein cholesterol, glucose and creatinine, and urine albumin/creatinine ratio treated as standard
covariates, and on-treatment heart rate and diastolic and systolic blood pressure treated as time-varying covariates.
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Figure 1. Rates of myocardial infarction (MI, Panel A), stroke (Panel B), cardiovascular
death (Panel C), the composite end point (Panel D), and all-cause mortality (Panel E) in
relation to the presence or absence of ECG left ventricular hypertrophy by both Cornell
product (CP) and Sokolow-Lyon voltage (SL) at study baseline. CI indicates confidence
interval; CV, cardiovascular.
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compared with the absence of LVH by both criteria, the
presence of LVH by both CP and SL was associated with
between 4.71- and 5.80-fold increased risks of cardiovascular
events, cardiovascular mortality and all-cause mortality and
the presence of LVH by one or the other criteria with
intermediate increased risks of events. After controlling for
randomized treatment with losartan or atenolol, age, sex,
prevalent diabetes mellitus, history of stroke, MI, ischemic
heart disease, heart failure, peripheral vascular disease or
prior antihypertensive treatment, baseline serum cholesterol,
high-density lipoprotein cholesterol, glucose and creatinine,
and urine albumin/creatinine ratio treated as standard
covariates, and on-treatment heart rate and diastolic and
systolic BPs treated as time-varying covariates, on-treatment
presence of ECG LVH by either criterion remained associated
with between 45% and 140% increased risk of events and the
presence of ECG LVH by both criteria was associated with a
>3-fold adjusted risk of all outcomes. There were no
significant differences in the predictive value of the combi-
nation of CP and SL for the composite end point in subgroups
of the LIFE study population stratified by sex, race, age,
history of ischemic heart disease, diabetes mellitus, or
randomized treatment allocation to losartan versus atenolol
(Table 4).
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Figure 2. Risk of myocardial infarction (Panel A), stroke (Panel B), cardiovascular death
(Panel C), the composite end point (Panel D), and all-cause mortality (Panel E) in relation to
the on-treatment presence or absence of ECG left ventricular hypertrophy by both Cornell
product (CP) and Sokolow-Lyon voltage (SL) treated as time-varying covariates in Cox
analyses. *Adjusted for randomized treatment, age, sex, prevalent diabetes mellitus, history
of stroke, myocardial infarction, ischemic heart disease, heart failure, peripheral vascular
disease or prior antihypertensive treatment, baseline serum cholesterol, high-density
lipoprotein cholesterol, glucose and creatinine, and urine albumin/creatinine ratio treated
as standard covariates, and on-treatment heart rate and diastolic and systolic blood
pressure treated as time-varying covariates. CI indicates confidence interval.
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Discussion
Previous work provides a conceptual framework for combin-
ing ECG LVH criteria to concentrate risk. A number of
studies, including in the LIFE population, have demonstrated
that serial assessment of either SL or CP can stratify risk of
cardiovascular outcomes and cardiovascular and all-cause
mortality.16–20 However, none of these earlier studies
analyzed whether combining these 2 criteria could further
concentrate risk. Based on the limited sensitivity of single
ECG LVH criteria, which utilize QRS voltage or voltage
duration product measurements, several studies have
demonstrated that defining ECG LVH by the presence of
either increased CP or SL increased ECG sensitivity and
population prevalence of LVH, but at the cost of lower
specificity.29,30 In analyses of baseline echocardiographic
data from the LIFE study,31 persistence of ECG LVH by both
CP and SL on ECGs performed at study baseline was
associated with increased LV chamber volume and wall
thickness, higher LV mass, and increased prevalences of
echocardiographic LVH and abnormal LV geometry compared
with the absence of ECG LVH by both criteria. Indeed, after
adjusting for the possible effects of age, sex, race, baseline
systolic BP, and body mass index on LV mass, the presence
of ECG LVH by both CP and SL was associated with a >4-fold
increased odds of echocardiographic LVH.31 Paralleling
outcome findings in the current study, the presence of
ECG LVH by either CP or SL alone was associated with
smaller increases in LV mass, abnormal LV geometry, and
echocardiographic LVH.31
Further supporting the construct of using 2 different ECG
LVH criteria together, combinations of ECG LVH with imaging-
derived LV mass determinations21,28 or QT prolongation37
carry higher risk than either finding alone. In an analysis of
4748 participants in MESA (Multi-Ethnic Study of Atheroscle-
rosis),21 only the presence of LVH on both ECG (by either CP
or SL) and cardiac MRI remained significantly associated with
an increased risk of a composite end point of cardiovascular
disease events after adjusting for other risk factors (HR, 1.77;
95% CI, 1.03–3.04), whereas neither LVH by ECG alone (HR,
1.20; 95% CI, 0.69–2.09) or on MRI alone (HR, 1.38; 95% CI,
0.98–1.96) were significantly associated with increased risk
in their fully adjusted Cox model. Similarly, in patients with
hypertension in the echocardiographic substudy of LIFE,28 the
incidence of hospitalization for new-onset heart failure was
markedly higher in patients with LVH on both echocardiog-
raphy and ECG (by either CP or SL) (4.9%) compared with
patients with echocardiographic LVH only (2.2%), ECG LVH
only (0.6%), or LVH on neither test (0%, P<0.01). After
controlling for other heart failure risk factors in this popula-
tion, the presence of LVH on both ECG and echocardiogram
remained associated with a >3-fold increased risk of new
heart failure (HR, 3.60; 95% CI, 1.24–10.49). Lastly, among
7506 participants in NHANES III (US Third National Health and
Nutrition Examination Survey), Soliman et al37 found that
after adjusting for other risk factors, risk of all-cause mortality
was highest in the group with concomitant ECG LVH by CP
and a prolonged heart rate–adjusted QT interval (HR, 1.63;
95% CI, 1.12–2.36) with intermediate adjusted mortality risks
in those with isolated ECG LVH (HR, 1.48; 95% CI, 1.24–1.77)
0
2
4
6
1
CP-/SL- CP+/SL- CP-/SL+ CP+/SL+
p<0.001
1.89
H
az
ar
d
R
at
io
95% CI
1.63-2.19
2.55
5.00
95% CI
2.03-3.20
95% CI
4.15-6.02
p<0.001
p<0.001
Univariate Cox Model
0
2
4
6
1
CP-/SL- CP+/SL- CP-/SL+ CP+/SL+
p<0.001
1.46
95% CI
1.24-1.71
H
az
ar
d
R
at
io
1.89
95% CI
1.48-2.41
3.11
95% CI
2.54-3.81
p<0.001
p<0.001
Multivariable Cox Model*
Composite End Point
0
2
4
6
1
CP-/SL- CP+/SL- CP-/SL+ CP+/SL+
p<0.001
1.71
H
az
ar
d
R
at
i o
95% CI
1.45-2.03
2.77
4.71
95% CI
2.16-3.55
95%CI
3.80-5.84
p<0.001
p<0.001
Univariate Cox Model
0
2
4
6
1
CP-/SL- CP+/SL- CP-/SL+ CP+/SL+
p<0.001
1.45
95% CI
1.20-1.74
H
az
ar
d
R
at
io
2.08
95% CI
1.59-2.74
3.14
95% CI
2.48-3.98
p<0.001
p<0.001
Multivariable Cox Model*
All-Cause Mortality
D
E
Figure 2. Continued
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and those with an isolated long QT interval (HR, 1.27; 95% CI,
1.12–1.46).
The current study builds on the above findings and
concepts and on the well-established prognostic value of
serial assessment of ECG LVH2,3,12,13,16–20 to demonstrate
that the combination of 2 different ECG LVH criteria can
dramatically concentrate risk in patients with hypertension
undergoing treatment compared with either criterion alone.
Taking advantage of the complimentary information provided
by SL and CP criteria, these findings suggest that the
persistence or development of ECG LVH by both criteria in the
face of substantial BP lowering can identify patients who
remain at >3-fold increased adjusted risk of cardiovascular
morbidity and cardiovascular or all-cause mortality. In
contrast, regression or absence of ECG by both criteria was
associated with the lowest event rates over time, whereas
persistence or development of LVH by either CP or SL, but not
the other, was associated with intermediate risks of adverse
outcomes (Figure 2). The high residual risk associated with
persistence or development of ECG LVH by both criteria
despite attaining similar levels of on-treatment BP (Table 2)
suggests that persistence of LVH by both criteria may identify
a subgroup of patients with hypertension in whom more
Table 4. Multivariable Cox Analyses to Assess the Predictive
Value of the Combination of On-Treatment CP and SL for the
LIFE Study Composite End Point in Relevant Subgroups of the
Study Population
Subgroup
Composite
End Point,
No. HR 95% CI
P Value for
Interaction
Sex 0.190
Female (n=4963) 476
CP+/SL 1.44 1.12–1.84
CP/SL+ 1.62 1.02–2.57
CP+/SL+ 3.02 2.18–4.18
Male (n=4230) 620
CP+/SL 1.44 1.17–1.78
CP/SL+ 1.99 1.49–2.66
CP+/SL+ 3.13 2.41–4.06
Race 0.154
White/other
(n=8660)
1021
CP+/SL 1.44 1.22–1.70
CP/SL+ 1.82 1.40–2.37
CP+/SL+ 3.20 2.60–3.95
Black (n=533) 75
CP+/SL 1.69 0.84–3.40
CP/SL+ 1.80 0.81–3.95
CP+/SL+ 1.87 0.79–4.42
Age 0.481
<65 y (n=3489) 250
CP+/SL 1.52 1.11–2.08
CP/SL+ 1.90 1.15–3.14
CP+/SL+ 4.60 3.08–6.88
≥65 y (n=5704) 846
CP+/SL 1.52 1.26–1.82
CP/SL+ 2.03 1.53–2.69
CP+/SL+ 2.98 2.36–3.77
History of ischemic
heart disease
0.969
No (n=7724) 802
CP+/SL 1.46 1.22–1.75
CP/SL+ 1.76 1.32–2.35
CP+/SL+ 3.06 2.42–3.87
Yes (n=1469) 294
CP+/SL 1.48 1.04–2.10
CP/SL+ 2.45 1.52–3.96
CP+/SL+ 3.50 2.32–5.27
Continued
Table 4. Continued
Subgroup
Composite
End Point,
No. HR 95% CI
P Value for
Interaction
Diabetes mellitus 0.140
No (n=7998) 854
CP+/SL 1.45 1.21–1.73
CP/SL+ 1.64 1.24–2.17
CP+/SL+ 3.02 2.40–3.79
Yes (n=1195) 242
CP+/SL 1.53 1.05–2.21
CP/SL+ 3.40 2.03–5.68
CP+/SL+ 3.44 2.17–5.45
Randomized treatment 0.209
Atenolol (n=4558) 588
CP+/SL 1.36 1.09–1.70
CP/SL+ 1.45 1.01–2.07
CP+/SL+ 2.62 1.98–3.47
Losartan (n=4605)
CP+/SL 508 1.55 1.23–1.96
CP/SL+ 2.44 1.74–3.41
CP+/SL+ 3.78 2.82–5.08
CI indicates confidence interval; CP, Cornell product; HR, hazard ratio; LIFE, Losartan
Intervention For Endpoint Reduction; SL, Sokolow-Lyon voltage.
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aggressive BP lowering could possibly improve their progno-
sis. However, the significantly increased risks of cardiovas-
cular death, stroke, and LIFE study composite end point in
patients with persistent LVH by CP criteria despite having
average on-treatment systolic BP ≤130 mm Hg38 raises the
possibility that additional BP lowering in patients who do not
adequately regress LVH may not improve prognosis. In
contrast, Soliman et al39,40 demonstrated that more intensive
BP reduction was associated with greater LVH regression and
lower rates of developing new LVH among patients with
hypertension and diabetes mellitus in the ACCORD (Action to
Control Cardiovascular Risk in Diabetes) study39 and patients
with diabetes mellitus in SPRINT (Systolic Blood Pressure
Intervention Trial),40 but that the greater LVH regression in
SPRINT did not appear to explain most of the reduction in
cardiovascular events. Further study will be required to
evaluate whether specifically targeting patients with persis-
tent LVH to further reduce BP and produce regression of LVH
can improve prognosis in this high-risk subgroup of patients
with hypertension.
Study Limitations
There are several limitations of the current study that warrant
mention. First, this is a post hoc analysis of data from a
randomized treatment trial that compared 2 different treat-
ment approaches to BP reduction. Although determining the
relationship of ECG LVH changes with treatment to outcome
was a planned secondary analysis of the LIFE study,17
evaluation of the combination of SL and CP criteria was not a
prespecified analysis. Because use of ECG LVH criteria to
select patients for LIFE32 increased the baseline risk of the
population, caution should be used in generalizing these
findings to patients with hypertension at lower risk or those
younger than 55 years. However, ECG LVH has demonstrated
significant risk stratification in populations that have varied
degrees of baseline risk and baseline prevalence of ECG
LVH,1–3,12,13,21,23–27 suggesting that these findings are likely
to apply in other, lower-risk hypertensive populations.
Conclusions
These findings have important implications for the manage-
ment of patients with hypertension. First, these observations
suggest that serial assessment of both CP and SL can
improve risk stratification in patients with hypertension during
treatment. More intriguingly, the residual high risk associated
with persistence or development of ECG LVH by both criteria
suggest that these patients might benefit from additional
therapy aimed at further lowering their BP and reducing their
ECG LVH to reduce risk. Further study is clearly warranted to
determine whether combining ECG LVH criteria similarly
concentrates risk in other patient populations and under other
treatment conditions and whether therapy targeted at
regression of ECG LVH in patients with persistence of ECG
LVH by both criteria can reduce risk or whether this risk
marker identifies a subset of patients with hypertension
whose prognosis is less likely to improve despite adequate BP
reduction.
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